METHOD FOR THE PREDICTION OF VASCULAR EVENTS AND THE DIAGNOSIS OF ACUTE CORONARY SYNDROME
The present invention relates to a method for the prognosis of a vascular event or the diagnosis of ACS in a patient suspected of being at risk for a vascular event or condition, said patient presenting: no elevation of the ST segment as seen on an electrocardiogram, and/or a normal level of at least one necrosis marker, wherein the presence and/or levels of at least two different biochemical markers are measured in a biological sample of said patient, whereby the probability that the patient will experience a vascular event or the vascular-related condition is deduced from the measured presence and/or levels of the biochemical markers.
1 . A method for the prognosis of a vascular event in a patient suspected of being at risk for a vascular event, said patient presenting:
no elevation of the ST segment as seen on an electrocardiogram, and/or
a normal level of at least one necrosis marker,
wherein the presence and/or levels of at least two different biochemical markers are measured in a biological sample of said patient, said biochemical markers being selected from the group consisting of the following classes of markers:
atherosclerotic plaque unstability markers,
atherosclerotic plaque disruption markers,
coronary inflammation markers,
pre-thrombotic status markers,
thrombosis markers,
ischemic markers,
necrosis markers, and
myocardial dysfunction markers,
whereby the probability that the patient will experience a vascular event is deduced from the measured presence and/or levels of the biochemical markers.
2 . The method for the prognosis of a vascular event according to claim 1 , wherein, the patient presents a chest pain.
3 . The method for the prognosis of a vascular event according to claim 1 , wherein the patient presents a normal cardiac Troponin level and/or a normal CK level.
4 . The method for the prognosis of a vascular event according to claim 1 , wherein the patient presents a normal cardiac Troponin I or cardiac Troponin T level and no elevation of the ST segment.
5 . The method for the prognosis of a vascular event according to claim 1 , wherein:
the atherosclerotic plaque unstability marker is selected from the group consisting of MPO, sCD40L, IL-6, PAPP-A and choline;
the atherosclerotic plaque disruption marker is selected from the group consisting of MPO, sCD40L, MMPs, Choline and PAPP-A;
the coronary inflammation marker is selected from the group consisting of MPO, sCD40L, CRP and IL-6;
the pre-thrombotic status marker is sCD40L or fibrinogen;
the thrombosis marker is selected from the group consisting of D-Dimers;
the ischemic marker is selected from the group consisting of IMA, cTnI, cTnT, and FABP;
the necrosis marker is selected from the group consisting of cTnI, cTnT, CK, myoglobin and FABP;
the myocardial dysfunction marker is selected from the group consisting of BNP, NT-proBNP and proBNP.
6 . The method for the prognosis of a vascular event according to claim 1 , wherein the biochemical markers are selected from the group consisting of the following combinations:
proBNP and PAPP-A, and optionally a marker selected from the group consisting of CRP, IL-6, MPO, sCD40L, D-Dimer, and BNP;
proBNP, IL-6, and a marker selected from the group consisting of CRP, sCD40L, and BNP;
proBNP and BNP, and optionally a marker selected from the group consisting of CRP, sCD40L, and MPO;
BNP or proBNP, and CRP, and optionally a marker selected from the group consisting of IL-6, MPO, PAPP-A, and D-Dimer;
proBNP or BNP, and sCD40L, and optionally a marker selected from the group consisting of CRP and MPO;
CRP and IL-6;
BNP or proBNP, and IL-6, and optionally CRP and MPO;
proBNP, PAPP-A, CRP, BNP, D-Dimer, IL-6, sCD40L, and MPO.
7 . The method for the prognosis of a vascular event according to claim 1 , wherein the vascular event is selected from the group consisting of myocardial vascular-related death, myocardial infarction, congestive-heart failure, vascular-related hospitalization, and revascularization procedure.
8 . A method for diagnosing an acute coronary syndrome (ACS) in a patient presenting:
no elevation of the ST segment as seen on an electrocardiogram, and/or
a normal level of at least one necrosis marker,
comprising measuring the presence and/or levels of at least two different biochemical markers in a biological sample of said patient, said biochemical markers being selected from the group consisting of the following classes of markers:
atherosclerotic plaque unstability markers,
atherosclerotic plaque disruption markers,
coronary inflammation markers,
pre-thrombotic status markers,
thrombosis markers,
ischemic markers,
necrosis markers, and
myocardial dysfunction markers,
whereby it is determined if said patient suffers from ACS.
9 . The method for diagnosing an ACS according to claim 8 , wherein the patient presents a chest pain.
10 . A method for diagnosing an ACS according to claim 8 , wherein the patient presents a normal cardiac Troponin level and/or a normal CK level.
11 . The method for diagnosing an ACS according to claim 8 , wherein the patient presents a normal cardiac Troponin I or cardiac Troponin T level and no elevation of the ST segment.
12 . A method for diagnosing ACS according to claim 8 , wherein the biochemical markers are selected from the group consisting of the following combinations of markers:
proBNP and PAPP-A, and optionally a marker selected from the group consisting of CRP, IL-6, MPO, sCD40L, D-Dimer, and BNP;
proBNP, IL-6, and a marker selected from the group consisting of CRP, sCD40L, and BNP;
proBNP and BNP, and optionally a marker selected from the group consisting of CRP, sCD40L, and MPO;
BNP or proBNP, and CRP, and optionally a marker selected from the group consisting of IL-6, MPO, PAPP-A, and D-Dimer;
proBNP or BNP, and sCD40L, and optionally a marker selected from the group consisting of CRP and MPO;
CRP and IL-6;
BNP or proBNP, and IL-6, and optionally CRP and MPO;
proBNP, PAPP-A, CRP, BNP, D-Dimer, IL-6, sCD40L, and MPO;
13 . A method for determining the condition of an individual suspected of having an ACS comprising measuring the presence and/or levels of at least two different biochemical markers in a biological sample of said patient, said biochemical markers being selected from the group consisting of the following combinations of markers:
proBNP and PAPP-A, and optionally a marker selected from the group consisting of CRP, IL-6, MPO, sCD40L, D-Dimer, and BNP;
proBNP, IL-6, and a marker selected from the group consisting of CRP, sCD40L, and BNP;
proBNP and BNP, and optionally a marker selected from the group consisting of CRP, sCD40L, and MPO;
BNP or proBNP, and CRP, and optionally a marker selected from the group consisting of IL-6, MPO, PAPP-A, and D-Dimer;
proBNP or BNP, and sCD40L, and optionally a marker selected from the group consisting of CRP and MPO;
CRP and IL-6;
BNP or proBNP, and IL-6, and optionally CRP and MPO;
proBNP, PAPP-A, CRP, BNP, D-Dimer, IL-6, sCD40L, and MPO;
whereby the condition of the individual is determined.
14 . The method for determining the condition of an individual suspected of having an ACS according to claim 13 , wherein the condition is selected from the group constituted of:
no ACS, and
unstable angina,
15 . The method for determining the condition of an individual suspected of having an ACS according to claim 13 , wherein (i) the level of at least one necrosis marker of the individual and (ii) the presence or absence of an elevation of the ST segment as seen on an electrocardiogram of the patient are determined.
16 . The method for determining the condition of an individual suspected of having an ACS according to claim 15 , wherein the necrosis marker is cardiac Troponin I or cardiac Troponin T.
17 . A kit intended for the prognosis of a vascular event in a patient, for diagnosing an ACS, or for determining the condition of an individual suspected of having an ACS, said kit comprising ligands specific respectively to the markers of the combinations of markers selected from the group constituted of:
proBNP and PAPP-A, and optionally a marker selected from the group consisting of CRP, IL-6, MPO, sCD40L, D-Dimer, and BNP;
proBNP, IL-6, and a marker selected from the group consisting of CRP, sCD40L, and BNP;
proBNP and BNP, and optionally a marker selected from the group consisting of CRP, sCD40L, and MPO;
BNP or proBNP, and CRP, and optionally a marker selected from the group consisting of IL-6, MPO, PAPP-A, and D-Dimer;
proBNP or BNP, and sCD40L, and optionally a marker selected from the group consisting of CRP and MPO;
CRP and IL-6;
BNP or proBNP, and IL-6, and optionally CRP and MPO;
proBNP, PAPP-A, CRP, BNP, D-Dimer, IL-6, sCD40L, and MPO.
18 . The kit according to claim 17 , comprising one specific ligand to cardiac Troponin I or cardiac Troponin T.
19 . The kit according to claim 17 , wherein the specific ligands are selected from the group constituted of:
polyclonal, monoclonal and recombinant antibodies, or fragments thereof,
phage antibodies (PhAbs),
llama and camel antibodies,
aptamers.